ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,490,000 | -12.8% | 134,979 | -12.0% | 0.01% | -15.4% |
| Q3 2016 | $10,882,000 | +45.9% | 153,399 | +0.6% | 0.01% | +44.4% |
| Q2 2016 | $7,461,000 | -21.9% | 152,553 | +1.1% | 0.01% | -25.0% |
| Q1 2016 | $9,554,000 | -49.3% | 150,913 | -10.1% | 0.01% | -50.0% |
| Q4 2015 | $18,832,000 | +17.3% | 167,869 | +0.7% | 0.02% | +9.1% |
| Q3 2015 | $16,058,000 | +5.6% | 166,729 | +12.3% | 0.02% | +15.8% |
| Q2 2015 | $15,208,000 | +397.3% | 148,529 | +201.5% | 0.02% | +375.0% |
| Q1 2015 | $3,058,000 | +50.4% | 49,258 | +6.3% | 0.00% | +33.3% |
| Q4 2014 | $2,033,000 | -22.6% | 46,331 | -0.2% | 0.00% | -25.0% |
| Q3 2014 | $2,628,000 | +28.5% | 46,424 | +1.9% | 0.00% | +33.3% |
| Q2 2014 | $2,045,000 | +120.1% | 45,555 | +139.6% | 0.00% | +200.0% |
| Q1 2014 | $929,000 | – | 19,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |